Welcome!

News Feed Item

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

NEW YORK, Jan. 23, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

http://www.reportlinker.com/p01081284/Global-Diabetes-Devices-Market-And...

Description

This report is an effort to identify factors, which will be the driving force behind the diabetes devices and drugs market and sub-markets in the next few years. The report provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the diabetes devices and drugs industry in terms of product and geography. We have used a combination of primary and secondary research to arrive at the market estimates, market shares and trends. We have adopted bottom up model to derive market size of the global diabetes devices and drugs market and further validated numbers with the key market participants and C-level executives.

This report highlights the industry with the following points:

Definition, estimates & forecast of diabetes devices and drugsproduct market from 2010 to 2018Analysis of product segments for diabetes devices and drugs product market with historical data and forecastTrends and forecast for four geographic markets, namely the U.S., Europe, Asia-Pacific, Middle East and Africa and Latin America based on segments of diabetes devices and drugs product marketProfiles of major market participants for better understanding of their contributions

This research is specially designed to estimate and analyze the demand and performance of diabetes devices and drugs products in a global scenario. The research provides in-depth analysis of diabetes devices and drugs product manufacturers, product sales, trend analysis by segments and demand by geography. The report covers all the major product segments of the global diabetes devices and drugs market, and provide historical data and statistically refined forecast for the segments covered. The study presents a comprehensive assessment of the stakeholder strategies and winning imperatives for them by segmenting the global diabetes devices and drugs market as below:

Diagnosis and Monitoring Devices Market

Blood Glucose Monitoring Devices

Lancets

Blood Sampling Devices

Blood Glucose Meters

New Development in Glucose Testing

Other Testing Devices

Hemoglobin A1c

Hemoglobin A1c Meters

Hemoglobin A1c Kits

Others

Software Programs for Diabetes Monitoring

Web Software

Commercial Software

Artificial Pancreas

Therapeutics Devices and Drugs Market

Insulin

By Action

Short Acting

Pre-Mixes

Long Acting

By Type

Human Insulin

Modern Insulin

Animal Insulin

By Purchase Type

Dosage

Bulk

Insulin Delivery

Syringes

Pens

Injectors

Inhaled Insulin

Insulin Pumps

Oral Hypoglycemic Agents

KATP Blocker

Biguanides

Alpha-Glucosidase Inhibitor

Thiazolinediones/ Glitazones

IncretinMimetics/ GLP-1 Analogs

DPP-4 Inhibitors

Amylin Mimetic

SGLT2 Inhibitors

Other

Cell Therapies

In addition the report provides a cross-sectional analysis of all the above segments with respect to following geographical markets:

North AmericaEuropeAsia-PacificMiddle East and AfricaLatin America

The in-depth research and high level analysis will allow diabetes devices and drugs product manufacturers, lawmakers, large retailers, medical companies and research and development agencies to make informed decisions about diabetes devices and drugs products manufacturing, designing marketing, growth strategies and gaining competitive advantage.?

TABLE OF CONTENTS

CHAPTER 1 PREFACE

1.1 REPORT DESCRIPTION

1.2 SCOPE OF THE REPORT

1.3 METHODOLOGY

1.4 ASSUMPTIONS

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL DIABETES MARKET ANALYSIS

3.1 DIABETES: AGE-GROUP ANALYSIS

3.2 MARKET OVERVIEW

3.3 KEY MARKET TRENDS

3.4 GLOBAL DIABETES MARKET SIZE AND FORECAST, 2010 – 2018

3.4.1 TYPE I DIABETES MARKET SIZE AND FORECAST

3.4.2 TYPE II DIABETES MARKET SIZE AND FORECAST

3.4.3 DIABETES DEVICES MARKET SIZE AND FORECAST

3.4.4 DIABETES DRUGS MARKET SIZE AND FORECAST

3.5 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)

3.6 MARKET DYNAMICS

3.6.1 DRIVERS

3.6.1.1 Growing Diabetic Population around the Globe

3.6.1.2 Changing Lifestyle and Obesity as a Leading Cause of Diabetes

3.6.1.3 Launch of New Generation Innovative Drugs Likely to Attract Consumers

3.6.2 RESTRAINTS

3.6.2.1 Lack of Awareness about Diabetes Diagnostics and Treatment

3.6.2.2 Adverse side-effects of drugs and the resulting litigation issues

3.6.3 OPPORTUNITIES

3.6.3.1 Increasing Awareness may Unleash the Untapped Market

3.7 IMPACT OF REGULATIONS ON TYPE II DIABETES MARKET GROWTH

3.7.1 RISE IN THE NUMBER OF BACKLOG OF DRUGS UNDER FDA REVIEW AND THE SHIFTING TIMELINES FOR THE SAME IN THE UNITEDSTATES

3.7.2 REGULATORS' LAY MORE EMPHASIS ON ADEQUATE SAFETY DATA INSTEAD OF RELYING ONLY ON EFFICACY DATA FOR DRUG APPROVAL AND NEW DIRECTIVES FOR PATIENT SCREENING IN THE UNITED STATES

3.7.3 PROMOTION OF LOW-COST GENERICS TO LIMIT HEALTHCARE COSTS, HEALTHCARE INSURERS' AND REGULATORS'

3.7.4 IN EMERGING MARKETS SUCH AS ASIA, PRICING CONTROLS ARE LIKELY TO BE PUT IN PLACE

3.8 FACTORS AFFECTING GLOBAL DIABETES DEVICES AND DRUGS MARKET

3.8.1 RISING INCIDENCE OF DIABETES IN KEY MARKETS SUCH AS U.S., U.K. AND GERMANY

3.8.2 RISING EDUCATION IS EXPECTED TO DECREASE DIABETES PREVALENCE BY 1.2%

3.8.3 PEOPLE WITH A DIABETES PARENT LEADS TO AN INCREASE OF 1.4%

3.8.4 SOCIAL FACTORS AFFECTING DIABETE

3.9 PORTERS FIVE FORECES ANALYSIS OF DIABETES DEVICES AND DRUGS MARKET

3.9.1 BUYERS' POWER

3.9.2 SUPPLIERS' POWER

3.9.3 EXISTING RIVALRY

3.9.4 THREAT OF NEW ENTRANTS

3.9.5 THREAT OF SUBSTITUTE

3.10 GLOBAL DIABETES DRUGS AND DEVICES REGULATORY SCENARIO

CHAPTER 4 GLOBAL DIABETES DEVICES AND DRUGS MARKET4.1 GLOBAL DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2010 – 20184.1.1 BLOOD GLUCOSE MONITORING DEVICES, MARKET SIZE AND FORECAST4.1.1.1 Lancets4.1.1.2 Blood Sampling Devices4.1.1.3 Blood Glucose Monitors4.1.1.3.1 Drivers4.1.1.3.1.1 Increasing awareness and simpler devices4.1.1.3.1.2 Increase in disposable income4.1.1.3.1.3 Declining prices4.1.1.3.1.4 Improving compatibility4.1.1.3.2 Restraints4.1.1.3.2.1 Increase in competition leading to low prices4.1.1.3.2.2 Private label brands4.1.1.3.2.3 Awareness among patients is still a challenge4.1.1.3.3 Key trends4.1.1.4 New Development in Glucose Testing4.1.2 OTHER TESTING DEVICES MARKET SIZE AND FORECAST4.1.2.1 Hemoglobin A1c4.1.2.1.1 Hemoglobin A1c Meters4.1.2.1.2 Hemoglobin A1c Kits4.1.2.2 Others4.1.3 SOFTWARE PROGRAMS FOR DIABETES MONITORING, MARKET SIZE AND FORECAST4.1.3.1 Web Software Programs for Diabetes Monitoring4.1.3.2 Commercial Software4.1.4 ARTIFICIAL PANCREAS, MARKET SIZE AND FORECAST4.2 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2011 – 20184.2.1 DRIVERS4.2.1.1 Improved Delivery Devices4.2.1.2 Increased Risk with Oral Anti-Diabetes Drugs4.2.1.3 Technological Advancement4.2.2 RESTRAINTS4.2.2.1 Associated Pain4.2.2.2 Market boom for New Generation diabetic drugs4.2.2.3 Cost Issues4.2.3 OPPORTUNITIES4.2.3.1 Novel insulin delivery method4.2.4 GLOBAL ORAL DIABETES DRUG MARKET4.2.4.1 Popular Anti-Diabetic Drugs World wide4.2.4.2 Drivers4.2.4.2.1 Novel drugs driving the market growth4.2.4.2.2 Patent expiry of popular drugs4.2.4.2.3 Painless Option4.2.5 RESTRAINTS4.2.5.1 Associated high risks4.2.5.2 Improving options of insulin delivery devices4.2.5.3 Trend of diabetic diet4.2.6 OPPORTUNITIES4.2.6.1 Diabetes Vaccines4.2.6.2 Leveraging the patent expiry of popular drugs4.2.7 INSULIN, MAKET SIZE AND FORECAST 4.2.7.1 Market Size and Forecast4.2.7.2 Global Insulin Market Share of Major Players, 2011 4.2.7 2.1 Global Human Insulin Market Share of Major Players, 2011 4.2.7 2.2 Global Modern Insulin Market Share of Major Players, 20114.2.7.3 Insulin Market Size and Forecast, By Action4.2.7.3.1 Short Acting4.2.7.3.2 Pre-Mixes4.2.7.3.3 Long Acting4.2.7.4 Insulin Market Size and Forecast, by Type4.2.7.4.1 Human Insulin4.2.7.4.2 Modern Insulin4.2.7.4.3 Animal Insulin4.2.7.5 Insulin Market Size and Forecast, by Purchase Type4.2.7.5.1 Dosage4.2.7.5.2 Bulk4.2.8 INSULIN, DELIVERY MAKET SIZE AND FORECAST4.2.8.1 Insulin Syringes Maket Size and Forecast 4.2.8.2 Insulin Pens Maket Size and Forecast4.2.8.3 Insulin Injectors Maket Size and Forecast 4.2.8.4 Inhaled Insulin Maket Size and Forecast 4.2.8.5 Insulin Pumps Maket Size and Forecast 4.2.8.5.1 Drivers4.2.8.5.1.1 Growing Diabetic Population4.2.8.5.1.2 Advancement in Technology4.2.9 ORAL HYPOGLYCEMIC AGENTS, MAKET SIZE AND FORECAST4.2.9.1 KATP Blocker Maket Size and Forecast4.2.9.2 Biguanides Maket Size and Forecast 4.2.9.3 Alpha-Glucosidase Inhibitor Maket Size and Forecast 4.2.9.4 Thiazolinediones/ Glitazones Maket Size and Forecast 4.2.9.5 Incretin Mimetics/ GLP-1 Analogs Maket Size and Forecast 4.2.9.6 DPP-4 InhibitorMaket Size and Forecast 4.2.9.7 Amylin Mimetic Maket Size and Forecast 4.2.9.8 SGLT2 Inhibitors Maket Size and Forecast 4.2.9.9 Other Oral Hypoglycemic Agents Maket Size and Forecast 4.2.10 CELL THERAPIES MAKET SIZE AND FORECAST

CHAPTER 5 GEOGRAPHY ANALYSIS

5.1 GLOBAL OVERVIEW

5.2 EUROPE DIABETES DEVICES AND DRUGS MARKET

5.2.1 INNOVATION DRIVING THE EUROPEAN MARKET

5.2.1.1 Undiagnosed patients high in European countries

5.2.1.2 Increasing R&D costs

5.2.2 RESTRAINTS

5.2.2.1 Case1

5.2.2.2 Case 2

5.2.2.3 Case 3

5.2.3 OPPORTUNITIES

5.2.3.1 Undiagnosed Diabetic Patient Population in Europe

5.2.4 EUROPE DIABETES MARKET SHARE OF MAJOR PLAYERS

5.2.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.2.5.1 Blood glucose monitoring devices, maket size and forecast

5.2.5.2 Other dibetes testing devices, maket size and forecast

5.2.5.3 Software programs for diabetes monitoring, maket size and forecast

5.2.5.4 Artificial pancreas, maket size and forecast

5.2.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.2.6.1 Insulin, maket size and forecast

5.2.6.2 Insulin delivery, maket size and forecast

5.2.6.3 Oral hypoglycemic agents, maket size and forecast

5.2.6.4 Cell therapies, maket size and forecast

5.3 ASIA PACIFIC DIABETES DEVICES AND DRUGS MARKET

5.3.1 CHINA

5.3.2 INDIA

5.3.3 SOUTH KOREA

5.3.4 TAIWAN

5.3.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.3.5.1 Blood glucose monitoring devices, maket size and forecast

5.3.5.2 Other dibetes testing devices, maket size and forecast

5.3.5.3 Software programs for diabetes monitoring, maket size and forecast

5.3.5.4 Artificial pancreas, maket size and forecast

5.3.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.3.6.1 Insulin, maket size and forecast

5.3.6.2 Insulin delivery, maket size and forecast

5.3.6.3 Oral hypoglycemic agents, maket size and forecast

5.3.6.4 Cell therapies, maket size and forecast

5.4 NORTH AMERICA DIABETES DEVICES AND DRUGS MARKET

5.4.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.4.1.1 Blood glucose monitoring devices, maket size and forecast

5.4.1.2 Other dibetes testing devices, maket size and forecast

5.4.1.3 Software programs for diabetes monitoring, maket size and forecast

5.4.1.4 Artificial pancreas, maket size and forecast

5.4.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.4.2.1 Insulin, maket size and forecast

5.4.2.2 Insulin delivery, maket size and forecast

5.4.2.3 Oral hypoglycemic agents, maket size and forecast

5.4.2.4 Cell therapies, maket size and forecast

5.5 MIDDLE EAST AND AFRICA DIABETES DEVICES AND DRUGS MARKET

5.5.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.5.1.1 Blood glucose monitoring devices, maket size and forecast

5.5.1.2 Other dibetes testing devices, maket size and forecast

5.5.1.3 Software programs for diabetes monitoring, maket size and forecast

5.5.1.4 Artificial pancreas, maket size and forecast

5.5.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.5.2.1 Insulin, maket size and forecast

5.5.2.2 Insulin delivery, maket size and forecast

5.5.2.3 Oral hypoglycemic agents, maket size and forecast

5.5.2.4 Cell therapies, maket size and forecast

5.6 LATIN AMERICDIABETES DEVICES AND DRUGS MARKET

5.6.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST

5.6.1.1 Blood glucose monitoring devices, maket size and forecast

5.6.1.2 Other dibetes testing devices, maket size and forecast

5.6.1.3 Software programs for diabetes monitoring, maket size and forecast

5.6.1.4 Artificial pancreas, maket size and forecast

5.6.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST

5.6.2.1 Insulin, maket size and forecast

5.6.2.2 Insulin delivery, maket size and forecast

5.6.2.3 Oral hypoglycemic agents, maket size and forecast

5.6.2.4 Cell therapies, maket size and forecast

CHAPTER 6 COMPETITIVE LANDSCAPE6.1 SUMMARY6.2 MARKET SHARE OF MAJOR PLAYERS: GLOBAL DIABETES MARKET6.3 GLOBAL DIABETES DEVICES MARKET SHARE OF MAJOR PLAYERS6.4 GLOBAL DIABETES THERAPEUTIC MARKET SHARE OF MAJOR PLAYERS6.4.1 INSULIN DELIVERY MARKET PLAYERS6.4.2 GLOBAL DIABETES DRUGS MARKET SHARES OF MAJOR PLAYERS6.5 CLINICAL TRIALS6.6 RECENT DEVELOPMENTS6.7 COMPETITIVE STRATEGY BY KEY PLAYERS

CHAPTER 7 COMPANY PROFILE

7.1 ABBOTT LABORATORIES

7.1.1 COMPANY OVERVIEW

7.1.2 REVENUE SHARE

7.1.3 RECENT DEALS

7.2 BRISTOL-MYERS SQUIBB (BMS)

7.2.1 COMPANY OVERVIEW

7.2.2 REVENUE SHARE

7.2.3 RECENT DEALS

7.3 DEXCOM

7.3.1 COMPANY OVERVIEW

7.3.2 REVENUE SHARE

7.3.3 RECENT DEALS

7.4 ELI LILLY

7.4.1 COMPANY OVERVIEW

7.4.2 REVENUE SHARE

7.4.3 RECENT DEALS

7.5 GLAXOSMITHKLINE

7.5.1 COMPANY OVERVIEW

7.5.2 REVENUE SHARE

7.5.3 RECENT DEALS

7.6 GLENMARK PHARMACEUTICALS

7.6.1 COMPANY OVERVIEW

7.6.2 REVENUE SHARE

7.6.3 RECENT DEALS

7.7 JOHNSON&JOHNSON

7.7.1 COMPANY OVERVIEW

7.7.2 REVENUE SHARE

7.7.3 RECENT DEALS

7.8 LUPIN

7.8.1 COMPANY OVERVIEW

7.8.2 REVENUE SHARE

7.8.3 RECENT DEALS

7.9 ROCHE

7.9.1 COMPANY OVERVIEW

7.9.2 REVENUE SHARE

7.9.3 RECENT DEALS

7.10 SANOFI

7.10.1 COMPANY OVERVIEW

7.10.2 REVENUE SHARE

7.10.3 RECENT DEALS

LIST OF FIGURES

FIG. 1 GLOBAL PREVALENCE OF DIABETES AMONG VARIOUS AGE GROUPS

FIG. 2 GLOBAL DIABETES PREVELANCE, BY COUNTRY 2011

FIG. 3 DRUGS VS. DEVICES MARKET SHARE

FIG. 1 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 2 TYPE-I DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 3 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 4 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 5 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 6 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)

FIG. 7 COUNTRY WISE DIABETES PATIENTS FORECAST, BY 2030 (MILLION)

FIG. 8 NUMBER OF DIABETES DRUGS IN DEVELOPMENT BY PHASE UNITED STATES, 2012

FIG. 9 NUMBER OF PEOPLE LEFT UNDIAGNOSED IN U.S., 2011 (MILLIONS)

FIG. 10 GLOBAL DIABETES DIAGNOSIS AND MONETORING MARKET SIZE AND FORECAST, BY CATEGORY 2010 - 2018 (USD MILLION)

FIG. 11 BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 12 LANCETS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 13 BLOOD SAMPLING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 14 MARKET SHARES (U.S. VS OTHERS)

FIG. 15 MARKET SHARE OF SMBG TESTING IN THE INVITRO- DIAGNOSTIC MARKET GLOBALLY

FIG. 16 BLOOD GLUCOSE METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 17 NEW DEVELOPMENTS IN GLUCOSE TESTING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 18 OTHER TESTING DEVICES BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 19 HEMOGLOBIN A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 20 HEMOGLOBIN A1C METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 21 HEMOGLOBIN A1C KITS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 22 OTHER A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 23 SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 24 WEB SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 25 COMMERCIAL SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 26 ARTIFICIAL PANCREAS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 27 MARKET SHARE

FIG. 28 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKETMARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 29 GLOBAL INSULINMARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)

FIG. 30 GLOBAL INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 31 GLOBAL MODERN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 32 GLOBAL HUMAN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011

FIG. 33 SHORT ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 34 PRE-MIXES INSULIN MARKET SIZE AND FORECAST, BY ACTION 2010 - 2018 (USD MILLION)

FIG. 35 LONG ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 36 HUMAN INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)

FIG. 37 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 38 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 39 INSULIN MARKET DOSAGE SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)

FIG. 40 INSULIN MARKET BULK SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)

FIG. 41 GLOBAL INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 42 INSULIN SYRINGES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 43 INSULIN PENS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 44 INSULIN INJECTORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 45 INHALED INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 46 INSULIN PUMPS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 47 KEY PARTICIPANTS: MARKET SHARES (2011)

FIG. 48 ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 49 KATP BLOCKER MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 50 BIGUANIDES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 51 ALPHA-GLUCOSIDASE INHIBITOR DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 52 THIAZOLINEDIONES/ GLITAZONES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 53 INCRETIN MIMETICS/ GLP-1 ANALOGS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 54 DPP-4 INHIBITORS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 55 AMYLIN MIMETIC DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 56 SGLT2 INHIBITORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 57 OTHER ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 58 CELL THERAPIES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)

FIG. 59 DIABETES PREVALENCE IN EUROPE

FIG. 60 POPULATION DISTRIBUTION WITH DIABETES (INITIATING DPP-IV, TZD, GLP-1 OR INSULIN)

FIG. 61 UNDIAGNOSED DIABETIC POPULATION

FIG. 62 EUROPEAN DIABETES DRUGS MARKET SHARE (2012)

FIG. 63 DISTRIBUTION OF DIABETES DRUG MARKET IN EUROPE

FIG. 64 DIABETES PREVALENCE IN ASIAN COUNTRIES

FIG. 65 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 66 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 67 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 68 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)

FIG. 69 MARKET SHARE OF ABBOTT LABORATORIES

FIG. 70 REVENUE SHARES OF ABBOTT LABORATORIES

FIG. 71 REVENUE TRENDS OF DEXCOM

FIG. 72 REVENUE TRENDS OF ELI LILLY

FIG. 73 REVENUE CONTRIBUTIONOF ELI LILLY

FIG. 74 REVENUE TREND OF GLAXOSMITH

FIG. 75 REVENUE TREND OF GLAXOSMITH

FIG. 76 REVENUE TREND OF GLENMARK PHARMACEUTICALS

FIG. 77 REVENUECONTRIBUTION OF JOHNSON&JOHNSON

FIG. 78 REVENUE TREND OF JOHNSON&JOHNSON

FIG. 79 REVENUE TREND OF LUPIN

FIG. 80 REVENUE TREND OF ROCHE

FIG. 81 REVENUE CONTRIBUTION OF SANOFI

FIG. 82 REVENUE TREND OF SANOFI

LIST OF TABLES

TABLE 1 OBESITY RATE IN THE U.S., BY STATE 2011 (%)

TABLE 2 CLINICAL TRIALS: US (ORAL ANTI-DIABETES DRUGS)

TABLE 3 CLINICAL TRIALS: CHINA (ORAL ANTI-DIABETES DRUGS)

TABLE 4 CLINICAL TRIALS: JAPAN (ORAL ANTI-DIABETES DRUGS)

TABLE 5 CLINICAL TRIALS: INDIA (ORAL ANTI-DIABETES DRUGS)

TABLE 6 CLINICAL TRIALS: UNITED KINGDOM (ORAL ANTI-DIABETIC DRUGS)

TABLE 7 CLINICAL TRIALS: GERMANY (ORAL ANTI-DIABETIC DRUGS)

TABLE 8 CLINICAL TRIALS: FRANCE (ORAL ANTI-DIABETIC DRUGS)

TABLE 9 CLINICAL TRIALS: US (ANTI-DIABETIC INJECTABLES)

TABLE 10 CLINICAL TRIALS: JAPAN (ANTI-DIABETIC INJECTABLES)

TABLE 11 CLINICAL TRIALS: CHINA (ANTI-DIABETIC INJECTABLES)

TABLE 12 CLINICAL TRIALS: INDIA (ANTI-DIABETIC INJECTABLES)

TABLE 13 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)

TABLE 14 CLINICAL TRIALS: UNITED KINGDOM (ANTI-DIABETIC INJECTABLES)

TABLE 15 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)

TABLE 16 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY GEOGRAPHY 2012 – 2018

TABLE 17 EUROPE DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 18 EUROPE DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2012 – 2018 (USD MILLION)

TABLE 19 EUROPE DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 20 ASIA PACIFIC DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 21 ASIA PACIFIC DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)

TABLE 22 ASIA PACIFIC THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 23 NORTH AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)

TABLE 24 NORTH AMERICA DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)

TABLE 25 NORTH AMERICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 29 LATIN AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 30 LATIN AMERICADIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 31 LATIN AMERICATHERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)

TABLE 32 CLINICAL TRIALS: UNITED STATES (INSULIN PUMPS)

TABLE 33 CLINICAL TRIALS: UNITED KINGDOM (INSULIN PUMPS)

TABLE 34 CLINICAL TRIALS: FRANCE (INSULIN PUMPS)

TABLE 35 CLINICAL TRIALS: GERMANY (INSULIN PUMPS)

TABLE 36 CLINICAL TRIALS: CHINA (INSULIN PUMPS)

TABLE 37 CLINICAL TRIALS: UNITED STATES (GLUCOSE MONITORS)

TABLE 38 CLINICAL TRIALS: UNITED KINGDOM (GLUCOSE MONITORS)

TABLE 39 CLINICAL TRIALS: FRANCE (GLUCOSE MONITORS)

TABLE 40 CLINICAL TRIALS: CHINA (GLUCOSE MONITORS)

To order this report:Drug_and_Medication Industry: Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
"Venafi has a platform that allows you to manage, centralize and automate the complete life cycle of keys and certificates within the organization," explained Gina Osmond, Sr. Field Marketing Manager at Venafi, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"We're focused on how to get some of the attributes that you would expect from an Amazon, Azure, Google, and doing that on-prem. We believe today that you can actually get those types of things done with certain architectures available in the market today," explained Steve Conner, VP of Sales at Cloudistics, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
For far too long technology teams have lived in siloes. Not only physical siloes, but cultural siloes pushed by competing objectives. This includes informational siloes where business users require one set of data and tech teams require different data. DevOps intends to bridge these gaps to make tech driven operations more aligned and efficient.
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
DXWorldEXPO LLC announced today that the upcoming DXWorldEXPO | CloudEXPO New York event will feature 10 companies from Poland to participate at the "Poland Digital Transformation Pavilion" on November 12-13, 2018.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors!
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.